drugset / Trial / NCT06826612
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RandomizedSequentialQuadruple-blindTreatment
Summary
The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.
Timeline
- Start
- 2025-02-21
- Primary completion
- 2035-01-12
- Completion
- 2035-01-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPK-10001 | Gene therapy (AAV / viral vector) | — | Other |